von Bernd Metzner ; Thomas H. Müller ; Jochen Casper ; Christoph Kimmich ; Claus-Henning Köhne ; Eduard Petershofen ; Andrea Renzelmann ; Ruth Thole ; Andreas Voß ; Martin Dreyling
von Emin Abbasov ; Bernd Metzner ; Thomas H. Müller ; Jochen Casper ; Christoph Kimmich ; Eduard K. Petershofen ; Andrea Renzelmann ; Bernd Rosien ; Ruth Thole ; Andreas Voß ; Claus-Henning Köhne
von Bernd Metzner ; Christiane Pott ; Thomas H. Müller ; Jochen Casper ; Christoph Kimmich ; Andrea Renzelmann ; Ruth Thole ; Andreas Voß ; Claus-Henning Köhne
von Veronika Brixner ; Gesine Bug ; Petra Pohler ; Doris Krämer ; Bernd Metzner ; Andreas Voß ; Jochen Casper ; Ulrich Ritter ; Stefan Klein ; Nael Alakel ; Rudolf Peceny ; Hans G. Derigs ; Frank Stegelmann ; Martin Wolf ; Hubert Schrezenmeier ; Thomas Thiele ; Erhard Seifried ; Hans-Hermann Kapels ; Andrea Döscher ; Eduard K. Petershofen ; Thomas H. Müller ; Axel Seltsam
Online first: 8 January 2021 ; Gesehen am 16.07.2021
First-line therapy for younger patients with peripheral T-cell non-Hodgkin lymphoma (T-NHL) consists of 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide (CHOEP), consolidated by high-dose therapy and autologous stem cell transplantation (auto-SCT). We hypothesized that allogeneic stem cell transplantation (allo-SCT) could improve outcomes. 104 patients with peripheral T-cell non-Hodgkin lymphoma, except ALK+ anaplastic large cell lymphoma, 18 to 60 years, all stages, and all age adjusted International Prognostic Index scores, except 0 and stage I, were randomized to 4 cycles of CHOEP and 1 cycle of dexamethasone, cytosine-arabinoside, and platinum (DHAP) followed by high-dose therapy and auto-SCT or myeloablative conditioning and allo-SCT. The primary end point was event-free survival (EFS) at 3 years. After a median follow-up of 42 months, the 3-year EFS after allo-SCT was 43%, as compared with 38% after auto-SCT. Overall survival at 3 years was 57% vs 70% after allo- or auto-SCT, without significant differences between treatment arms. None of the 21 responding patients proceeding to allo-SCT relapsed, as opposed to 13 of 36 patients (36%) proceeding to auto-SCT. Eight of 26 patients (31%) and none of 41 patients died of transplant-related toxicity after allo- and auto-SCT, respectively. The strong graft-versus-lymphoma effect after allo-SCT was counterbalanced by transplant-related mortality. This trial is registered at www.clinicaltrials.gov as #NCT00984412.
Blood Washington, DC : American Society of Hematology, 1946 137(2021), 19 vom: 13. Mai, Seite 2646-2656 Online-Ressource
